NOVAVAX COVID-19 Vaccine and Myocarditis: New October 2023 papers raise SERIOUS CONCERNS! The Good, The Bad and the Ugly regarding Novavax "2023-2024 Formulation"

Papers Reviewed:

• Oct.26, 2023 Wilkinson et al - A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

• Oct.18, 2023 - COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024

• June 2023 Smith et al - Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials

• Feb.2023 Saint-Gerons et al - Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase

• Dec.2022 Ahmad et al - Myopericarditis following both BNT162b2 and NVX-CoV2373

• June 7 2022 - U.S. Food and Drug Administration. Novavax COVID-19 vaccine (NVX-CoV2373) VRBPAC briefing document. Updated 2022